West Pharmaceutical Services Inc reported second-quarter 2026 results with revenue of $872.3M, net income of $154M and diluted EPS of $2.15, each up versus the prior-year quarter as the company benefited from strong demand for higher‑value proprietary products and devices.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$872.3M$766.5M13.8% | Net income²$154M$131.8M16.8% | Diluted EPS³$2.15$1.8218.1% |
¹ Reported as “Net sales”. ² Reported as “Net income”. ³ Reported as “Diluted income per share”.
Business Highlights
- Revenue growth was driven by Proprietary Products HVP components and devices, with strong demand for biologics and GLP‑1 HVP components and self‑injection devices (SmartDose) shifting mix toward higher‑value products.
- The company renamed a segment to West Vantage to align strategy and agreed to sell the SmartDose® 3.5mL business to AbbVie, with the transaction expected to close in July 2026.
- Gross margin expanded due to favorable product mix and price increases, though a May 2026 cyber incident caused about $7M of revenue downtime and some production inefficiencies.
- West continued targeted R&D and capacity investments in injectables, containment and self‑injection systems to support its pipeline and commercial demand.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.